![Takis and Rottapharm Biotech announce favourable preliminary results from the phase I clinical trial of COVID-eVax, a DNA-based vaccine candidate against COVID-19 - Rottapharm Biotech Takis and Rottapharm Biotech announce favourable preliminary results from the phase I clinical trial of COVID-eVax, a DNA-based vaccine candidate against COVID-19 - Rottapharm Biotech](https://www.rottapharmbiotech.com/wp-content/uploads/2019/01/news-and-pubblications.jpg)
Takis and Rottapharm Biotech announce favourable preliminary results from the phase I clinical trial of COVID-eVax, a DNA-based vaccine candidate against COVID-19 - Rottapharm Biotech
![Applied DNA Subsidiary, LineaRx, Inc. Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines - Applied DNA Sciences Applied DNA Subsidiary, LineaRx, Inc. Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines - Applied DNA Sciences](https://adnas.com/wp-content/uploads/2018/08/iStock-867398442.jpg)
Applied DNA Subsidiary, LineaRx, Inc. Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines - Applied DNA Sciences
![Applied DNA and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate | Business Wire Applied DNA and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate | Business Wire](https://mms.businesswire.com/media/20200916005287/en/593924/23/box-logo-businesswire.jpg)
Applied DNA and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate | Business Wire
![Takis and Rottapharm Biotech announce favourable preliminary results from the phase I clinical trial of COVID-eVax, a DNA-based vaccine candidate against COVID-19 - Rottapharm Biotech Takis and Rottapharm Biotech announce favourable preliminary results from the phase I clinical trial of COVID-eVax, a DNA-based vaccine candidate against COVID-19 - Rottapharm Biotech](http://www.rottapharmbiotech.com/wp-content/uploads/2015/10/logo3.png)
Takis and Rottapharm Biotech announce favourable preliminary results from the phase I clinical trial of COVID-eVax, a DNA-based vaccine candidate against COVID-19 - Rottapharm Biotech
![LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction - Applied DNA Sciences LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction - Applied DNA Sciences](https://adnas.com/wp-content/uploads/2019/09/doctor-visualizing-results.jpg)